Mesenchymal Stem Cells (MSCs)

Mesenchymal stem cells (MSCs) are a well-characterized population of adult stem cells that can differentiate into a variety of cell types (chondrocytes, osteoblasts, adipocytes, myocytes, and more).

Longeveron Wins $6.7 Million in Grant Funding, Including a $750,000 MSCRF Award

October 30, 2018 By Cade Hildreth, Founder & President Leave a Comment

Longeveron LLC is a regenerative medicine company developing cellular solutions for aging-related diseases. The company is focused on the development of allogeneic (donor-derived) human mesenchymal stem cells (MSCs) that are harvested and grown at its manufacturing facility in Miami, Florida.

Longeveron’s MSC (LMSC) product is derived from the bone marrow of young, healthy adult donors.

In addition to manufacturing its own cells in this cGMP facility, Longeveron is conducting clinical trials and manufacturing cells for other parties through its cell therapy CMO business. A contract manufacturing organization (CMO) is a company that provides manufacturing services to cell and gene therapy companies on a contract basis. [Read more…]

Interview with Kyle Cetrulo, CEO of AuxoCell Laboratories

September 11, 2018 By Cade Hildreth, Founder & President Leave a Comment

This is an interview with Kyle Cetrulo, Founder and CEO of AuxoCell Laboratories, a company specializing in solid tissue processing using its AC:Px System. In addition to heading Auxocell and being a thought-leader on perinatal stem cells, Kyle is an organizer for the upcoming 2^nd Annual Perinatal Stem Cell Society Conference that will take place each March in Aspen, CO.
[Read more…]

Dr. Paul Wotton on the Future of Cynata Therapeutics’ Novel iPSC-Derived MSCs

July 10, 2018 By Cade Hildreth, Founder & President Leave a Comment

This is an interview with Dr. Paul Wotton, who joined Cynata Therapeutics Board of Directors in June, 2016. Dr. Wotton was previously President and CEO of Ocata Therapeutics, Inc. (NASDAQ: OCAT) joining the company in July 2014 and managing it through an all-cash take-over by Astellas Pharma valued at $379 million. [Read more…]

Eppendorf introduces first ready-to-use, synthetic cell cultureware for iPSC and MSC stem cells

July 3, 2018 By Cade Hildreth, Founder & President Leave a Comment

Hamburg, June 2018 – Since the groundbreaking discovery of human induced pluripotent stem cells (hiPSCs) by Shinya Yamanaka in 2006, the use of pluripotent stem cells (PSCs) has experienced a boom. Due to their extensive in vitro self-renewal properties and their ability to differentiate into many different cell types, PSCs, and especially hiPSCs, offer exciting promises in a wide range of cell applications including regenerative medicine. [Read more…]

Cynata Reports Positive 28-day Data from Cohort B of Phase 1 Trial of CYP-001 in GvHD

June 27, 2018 By Cade Hildreth, Founder & President Leave a Comment

MELBOURNE, Australia, June 21, 2018 — Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX:CYP) is pleased to announce positive safety and efficacy data from a day 28 analysis of patients in Cohort B of its Phase 1 clinical trial of CYP-001, the Company’s lead Cymerus™ mesenchymal stem cell (MSC) product candidate, in steroid-resistant acute graft-versus-host disease (GvHD). [Read more…]